Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00FZN
|
|||
| Former ID |
DNC013463
|
|||
| Drug Name |
Tyr-(R)-Aba-Gly-Phe-NH2
|
|||
| Synonyms |
CHEMBL250448; Tyr-(R)-Aba-Gly-Phe-NH2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H33N5O5
|
|||
| Canonical SMILES |
C1C(C(=O)N(CC2=CC=CC=C21)CC(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)C(CC4=CC=C(C=C4)O)N
|
|||
| InChI |
1S/C30H33N5O5/c31-24(14-20-10-12-23(36)13-11-20)29(39)34-26-16-21-8-4-5-9-22(21)17-35(30(26)40)18-27(37)33-25(28(32)38)15-19-6-2-1-3-7-19/h1-13,24-26,36H,14-18,31H2,(H2,32,38)(H,33,37)(H,34,39)/t24-,25-,26+/m0/s1
|
|||
| InChIKey |
XIRBKSHTAOQLGM-KKUQBAQOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [1] |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.